dr. eggermont on the impact of adjuvant anti–pd-1 agents in melanoma
Published 6 years ago • 172 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
1:39
dr. eggermont on the rationale for evaluating adjuvant pembrolizumab in advanced melanoma
-
1:53
dr. eggermont discusses impact of pembrolizumab in melanoma
-
8:01
anti–pd-1 adjuvant therapy in melanoma
-
1:34
dr. eggermont on responses to adjuvant pembrolizumab in stage iii melanoma subtypes
-
6:23
adjuvant therapy options in melanoma treatment
-
4:29
anti–pd-1 therapy in metastatic melanoma
-
4:01
adjuvant pd-(l)1 inhibitors for melanoma
-
7:03
adjuvant therapy for melanoma
-
2:06
dr. tarhini discusses adjuvant therapy for melanoma
-
9:18
adjuvant immunotherapy for melanoma
-
1:24
dr. atkins on adjuvant ipilimumab in melanoma
-
8:10
novel therapies in metastatic melanoma
-
4:25
the phenomenon of immunotherapy in melanoma
-
1:49
dr. luke on the fda approval of adjuvant nivolumab in melanoma
-
5:37
pd-1 inhibitor use in melanoma
-
4:59
adjuvant therapy options in melanoma
-
1:43
dr. topalian on biomarkers for anti- pd-1 therapies in melanoma
-
2:35
beyond anti-pd-1 and anti-ctla-4 in melanoma
-
8:47
adjuvant therapy in melanoma: targeted vs immuno-oncology